Ironwood Pharmaceuticals

Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds
Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds
BioSpace
Ironwood Pharmaceuticals
Cyclerion
spinoffs
orphan diseases
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Ironwood spinout Cyclerion planning $175M private placement
Ironwood spinout Cyclerion planning $175M private placement
BioCentury
Cyclerion
Ironwood Pharmaceuticals
Flag link:
Ironwood to cut 35 more jobs as company split nears
Ironwood to cut 35 more jobs as company split nears
BioPharma Dive
Ironwood Pharmaceuticals
layoffs
spinoffs
Cyclerion
Flag link:
Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463
Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463
Pharmaceutical Business Review
Ironwood Pharmaceuticals
IW-6463
CNS disorders
clinical trials
Flag link:
Ironwood names AstraZeneca exec as CEO; shares up 8%
Ironwood names AstraZeneca exec as CEO; shares up 8%
Seeking Alpha
Ironwood Pharmaceuticals
AstraZeneca
Mark Mallon
Flag link:
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Ironwood, Allergan set to resolve LINZESS patent litigation with Mylan
Pharmaceutical Business Review
Ironwood Pharmaceuticals
Mylan
patents
Linzess
Flag link:
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Motley Fool
Novartis
crizanlizumab
sickle cell disease
Ironwood Pharmaceuticals
IW-1701
Flag link:
Ironwood secures FDA fast track designation for heart drug praliciguat
Ironwood secures FDA fast track designation for heart drug praliciguat
Pharmaceutical Business Review
Ironwood Pharmaceuticals
FDA
praliciguat
heart failure
Flag link:
Linzess Receives Additional Indication in Japan for Chronic Constipation
Astellas
Ironwood Pharmaceuticals
Linzess
Flag link:
Ironwood Initiates Ph III Study of Linaclotide in IBS-C
Ironwood Initiates Ph III Study of Linaclotide in IBS-C
CP Wire
Ironwood Pharmaceuticals
Allergan
linaclotide
Linzess
IBS-C
Flag link:
Ironwood Initiates Ph III Study of Linaclotide in IBS-C
Ironwood Pharmaceuticals
Allergan
linaclotide
Linzess
IBS-C
Flag link:
Ironwood’s preparation for activist-driven R&D split puts 40 staffers out of work
Ironwood’s preparation for activist-driven R&D split puts 40 staffers out of work
Fierce Pharma
Ironwood Pharmaceuticals
R&D
layoffs
Flag link:
Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation
Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation
BioSpace
Ironwood Pharmaceuticals
FDA
sickle cell disease
olinciguat
orphan drug
Flag link:
Ironwood pushing through mid-stage trials with nephropathy drug
Ironwood pushing through mid-stage trials with nephropathy drug
BioPharma Dive
Ironwood Pharmaceuticals
clinical trials
diabetic nephropathy
IW-1973
Flag link:
Allergan: Is Linzess 'Restasis 2.0'?
Allergan: Is Linzess 'Restasis 2.0'?
NY Shock Exchange
Allergan
Restasis
patents
Linzess
Ironwood Pharmaceuticals
Teva Pharmaceutical
IBS-C
Flag link:
Ironwood zeroes in on primary care doctors with new gout combo med Duzallo
Ironwood zeroes in on primary care doctors with new gout combo med Duzallo
Fierce Pharma
Ironwood Pharmaceuticals
gout
Duzallo
primary care
Flag link:
AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million
AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million
BioPharma Dive
AstraZeneca
Zurampic
Ironwood Pharmaceuticals
gout
Flag link:
Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess
Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess
Fierce Pharma Marketing
Ironwood Pharmaceuticals
Allergan
Linzess
Flag link:
Is This Ironwood Pharmaceuticals' Biggest Threat?
Is This Ironwood Pharmaceuticals' Biggest Threat?
Motley Fool
Ironwood Pharmaceuticals
Linzess
plecanatide
Synergy Pharmaceuticals
Flag link:

Pages